Technology

Minimize

SEED Capital makes technology investments broadly within software, mobile, hardware and industrial technologies. It is often in the mix between known solutions and new technology or between known technology and new challenges that unexpected opportunities arise, and we would rather be surprised than discard solutions not within our target focus.

Abeo

Super Light Concrete Structures

Technology: 

Abeo has developed a cost-efficient concrete technology and building method consisting of a skeleton of medium to strong concrete in combination with an external layer of very light concrete.

Value Proposition: 

Abeo improves the strength of a concrete construction while cutting the overall weight in half, which lowers material costs and reduce CO2 emissions from production, transport and construction. The technology can be applied in most concrete buildings and structures.

Portfolio Manager: 
www.abeo.dk Hans Terney Rasmussen (CEO)

ahandyhand

Peer to peer network platform

Technology: 

aHandyHand wants to systematize and categorize the market for services and tasks. aHandyHand aims at establishing themselves as the central peer to peer network platform for delivery of help and assistance with any task, for all clients, by all capable providers. 

Value Proposition: 

Private individuals and households often need help with smaller tasks such as babysitting, installing or troubleshooting new IT/technology purchases, gardening and educational assistance etc. Traditionally, individuals would recruit a person, willing and capable of completing the task, from their network of friends or family or by posting an ad on the bulletin board in the local supermarket. aHandyhand wishes to make it easier for people in need of services and people who offer services, to find each other. For providers, aHandyHand promises to turn unused time into cash and for clients, aHandyHand offers a user-friendly and manageable platform for getting tasks done.       

Portfolio Manager: 
ahandyhand.dk/Christian Arensbak

Amminex ET

NOx exhaust removal from diesel vehicles

Technology: 

Amminex ET's core technology is called ASDS - Ammonia Storage and Delivery System. It allows ammonia to be safely, chemically stored in metal ammine complexes with the same volume metric capacity as pressurized liquid ammonia, which in turn can help drastically reduce NOx from the exhaust of diesel vehicles. NOx is a toxic air pollutant participating in formation of smog, ozone layer depletion and acid rain.The ASDS can also be used to supply hydrogen or ammonia to fuel cell systems.

Value Proposition: 

A number of laws have been passed both in the EU and the US, setting limits for NOx levels in exhaust. Amminex ET's solution removes NOx from exhaust accommodating these laws and greatly benefitting the environment.The possibility to use the ASDS technology to store hydrogen as ammonia also provides an opportunity to use an extremely clean, carbon-free and renewable energy source in a variety of ways.

Additional Information: 

Co-investors: Nordea-Foundation (DK), Faurecia Exhaust International (F)

Portfolio Manager: 
www.amminex.netAnnika Isaksson (CEO), Peter Terry Ward (BoD-Chairman)

Bellmetric

Calltracker

Technology: 

Bellmetric has developed an algorithm, which makes it possible to document the coherence between online activity and incoming calls through the Bellmetric CallTracker. 

Value Proposition: 

Companies with complex products such as insurance, banking, telecom and travel often rely on inbound calls to finalize sales. Phone leads are vital for sales and therefore for the companies’ marketing divisions. Call Tracking allows marketing departments with a multi channel setup to extract data regarding the efficiency of various online (and offline) marketing efforts lead generation; thereby increasing the efficiency of their marketing efforts. The Bellmetric CallTracker allows call centers to gain live and historical information on a caller’s activity on the company’s web page. This enables call centers to route calls intelligently based on business area, sales staff effectiveness and customers history; ultimately increasing the conversion efficiency of the call centers.

Portfolio Manager: 

Blackwood Seven

Media analytics platform

Technology: 

Blackwood Seven has developed the world’s first automated media allocation platform.

Value Proposition: 

Blackwood Seven's platform allows advertisers to plan and execute campaigns across all media groups on the basis of performance data. The company’s vision is simple – to give insight and power back to advertisers.   

Portfolio Manager: 

BluePrinter

Printing in 3D

Technology: 

As a common (2D) printer prints on paper a Blueprinter 'prints' 3-dimensional objects based on 3D CAD computer models.

Value Proposition: 

Blueprinter creates an easy-to-use and robust office machine that prints precise high quality models with no post processing requirements. Their offering is highly competitive compared to existing solutions.

Portfolio Manager: 
www.blueprinter.dk Niels Appel (CEO), Jeppe Frandsen (CoB)

Bookingabus.com

Online bus rental

Technology: 

Bookingabus.com is the world’s first online portal for bus rental. Bookingabus.com provides customers with a choice between several reliable bus operators, instant pricing based on the costumers needs and the opportunity to book rental busses from anywhere at any time. 

Value Proposition: 

Today costumers and bus operators communicate through traditional channels like phone or email. This process is time-consuming and makes comparison between operators nearly impossible. Today 75% of all hotel and airline travel is booked online, while only 1% of bus rentals are carried out. Bookingabus.com wishes to change this.

Bookingabus.com offers their costumers a range of choices between operators, instant pricing and transparent operator presentation. Furthermore, the costumer now has the opportunity to book outside office hours. The operators are offered online presence and an expansion of costumer segment, while saving time on answering requests. 

Portfolio Manager: 

Bownty

Deal aggregator

Technology: 

Bownty is an aggregator of deals - meaning offers limited in time or numbers. They gather and sort deals from more than 100 european dealsites, which are then passed on to consumers via bownty.com and partnership sites.

Value Proposition: 

The number of dealsites has exploded over the last period making it virtually impossible for the user to maintain an overview. The consequence being that users risk missing out on the best or most relevant deals. Bownty is the answer to this concern. With Bownty users get an overview of all deals and the possibility to receive only a specific  number of deals.

Portfolio Manager: 
www.bownty.comSteffen W. Frølund

Codesealer

Web banking protection services

Technology: 

Codesealer has developed a patented sealed code technology, which makes it practically impossible for cybercriminals to operate. The technology pushes out a unique and frequently changing java-applet to the user upon login making the window of opportunity for the trespasser extremely narrow.

Value Proposition: 

The banking industry loses 1 billion $ every year to cyber criminality despite spending more than 7 billion $ attempting to prevent it. Codesealer help banks to reduce losses from cybercriminals with at least 50%. Additionally Codesealer is implemented in the bank's infrastructure and is therefore invisible for the user.

Portfolio Manager: 

Dealcircle

Investment community

Technology: 

Dealcircle aims at providing investors and business angels with a networking platform on which they can introduce and share recommended investments with each other. Dealcircle cultivates a closed community, which enables investors to work with trusted peers, accelerator programs and top business angels. 

Value Proposition: 

In EU alone, business angels invest EUR 5.1 billion each year. Many of these investors prefer trusted networks involving a minimum of exposure, which is what Dealcircle offers. Dealcircle is a private network of trusted individuals, where investment opportunities are shared and recommended to potential co-investors. The platform provides investors with tools to lessen the work associated with startup investments and makes co-investment easier.

Dealcircle is international from launch and provides cross border legal paperwork - thereby making cross border investments possible to the entire Dealcircle community. Furthermore Dealcircle will provide startup match making, high deal flow quality and trusted peers with the capital and the necessary skills.  

Portfolio Manager: 
www.dealcircle.coBertrand Bisson (Founder & CEO), Lars Buch (Co-Founder & Chairman)

Deskwolf

Social media marketing

Technology: 

Deskwolf offer a ”social media marketing” service to Small and mid-sized companies in the Business-to-Consumer space. Deskwolf has built a user-friendly CMS-system, that lets ordinary, non-technical users edit and manage their Facebook pages. The system allows customers to set-up and manage a series of ”apps”, for running contact forms, competitions, e-mail signup, coupon deal features, etc. on their Facebook page.

Value Proposition: 

Today, SMB’s in the Business-to-Consumer space mainly generate new business via word-of-mouth, marketing in local papers, yellow pages and websites. Facebook offers new, more cost-efficient and measurable ways to reach a specific target audience, build on-going relations with customers and potential customers and gather personal data on a target audience. For small businesses with limited sales- and marketing resources and expertise, creating and managing a professional and effective Facebook solution is complex and as technically demanding as building a website. Deskwolf’s service is a pre-packaged ”turn-key” Facebook solution, aimed at serving the needs of SMB’s.

Portfolio Manager: 
Rasmus Aaen Madsen

Endomondo

Social sportstracking community

Technology: 

Endomondo provides an online service for tracking, monitoring and coaching your physical activities such as running, biking, walking, skiing etc. It further provides an online community for sharing results and challenging friends as well as a mobile app that can track results real-time using the built-in GPS as well as coach the user with lap times and music. The app is available on all major mobile platforms.

Value Proposition: 

It is always more motivating and fun to do sports if you can track your progress and if you can do it with others to support, coach and challenge you. By providing a platform for tracking activities as well as sharing and challenging friends Endomondo help users stay motivated towards physical activities. Something of great focus in most western countries.More than 10 million people have downloaded the mobile application.

Additional Information: 

Co-investors: Several Business Angels

Portfolio Manager: 
www.endomondo.com Christian Bernitt Birk, Preben Damgaard (CoB)

Expanite

Hardening of metals

Technology: 

Expanite has developed a fast and cost-efficient process for superior surface hardening of stainless steel. The solution works by dissolving nitrogen or carbon atoms into cavities in the crystal structure of the steel.

Value Proposition: 

Stainless steel products that have been hardened by the Expanite technology has up to 100x better lifetime, they have better corrosion properties, and they are virtually impossible to scratch. Further, Expanite’s technology is not restricted by the size of the product benefitting from the hardening.Expanite is currently testing their solution with international companies.

Portfolio Manager: 
www.expanite.com Thomas Abel Sandholdt (CEO), Thomas Strabo Hummelshøj (CTO), Thomas Folmann (CoB)

Firmafon

Telephone solution for small and medium sized enterprises

Technology: 

Firmafon provides a telephone solution for small and medium sized enterprises. The solution works as a web-based switchboard (virtual PBX) integrated with a mobile virtual network operator (MVNO) and is executed as a simple and intuitive web based user interface (SaaS).

Value Proposition: 

Firmafon's solution provides smaller sized enterprises with telephone features that would normally only be available for larger companies. The solution is very price competitive and very user friendly.

Portfolio Manager: 
www.firmafon.dkPeter Engelbrecht (CEO), Niklas Stephenson (CTO)

Gasp Solar

Solar Cells

Technology: 

Gasp Solar has invented a technology for a high-efficiency solar cell based on standard silicon solar cells, on which nanowires made from gallium-arsenide-phosphate (GaAsP) are grown. The combination of the two materials results in a tandem junction solar cell, which means that the solar cell can transform two different parts of the sunlight’s spectre into energy.     

Value Proposition: 

The solar cell will have an energy conversion efficiency of 35% enabling effective use of solar cells on mobile devices.

 

Portfolio Manager: 

GreenGo Energy

solar panel solution

Technology: 

GreenGo Energy is an energy company offering its customers significantly lower electricity bills and a greener profile.
 

Value Proposition: 

The business model is based on a full-size service concept, where electricity is produced by solar panels placed on the customers’ roofs, while GreenGo Energy takes care of everything related to the product – installation, maintenance, and financing.  Customers are cash-positive from day 1 and are guaranteed a minimum production level for 30 years.

Focusing on large scale customers GreenGo Energy has a reference list including major property owners, housing associations and several Danish municipalities.

Portfolio Manager: 

IEV

Industrial Electrical Vehicle

Technology: 

IEV has developed an industrial electrical vehicle enabling postal services to significantly increase effectiveness of mail delivery. The vehicle will be able to service routes of 30 to 60 km and have a load capacity of 240kg.

Value Proposition: 

Postal services around the world are experiencing a steady decline in postal volume as a result of e-communication and public digitalisation. As a result of the decline in postal volume the national postal services are undergoing a major structural change requiring them to change many of the basic principles for delivering mail. The industrial electrical vehicle will enable postal services to reap significant savings on fuel and maintenance compared to the currently employed commercial gasoline fuelled scooters.

Portfolio Manager: 
Ivan Loncarevic

Ivisys

Automated visual quality control System

Technology: 

Ivisys has developed an automated visual quality control system, which is to be used to ensure optimal quality control of manufactured parts and products. Ivisys’s innovation is a flexible machine vision solution that covers a wide area of industrial quality control applications.  

Value Proposition: 

Ivisys’s novel solution significantly improves performance, flexibility and robustness compared to today’s machine vision solutions and it allows for quality control of more complex and advanced components. The system enables customers to automate quality inspection tasks previously impossible to automate, which will lower the quality control costs and secure consistent and higher quality output. Ivisys’s solution can be used in multiple industrial contexts.

Portfolio Manager: 
Jakob Kesje (CEO), Moatasem Chehaiber (CTO)

Leikr

Training solutions for endurance sports athletes

Technology: 

Leikr develops stylish GPS watches build on an open platform with integrated downloadable services. 

Value Proposition: 

Current GPS watch offers are limited and clunky and run on generic proprietary platforms in closed ecosystems.

At the same time on-line communities are growing at a fast pace and the most popular ones, like Endomondo, SportsTracker and TrainingPeaks, can count a consumer base of several millions.

Leikr delivers a complete training solution for the modern endurance sports athletes and amateurs. Through a  range of small, full featured, elegantly designed sports watches that are easy to operate, Leikr will deliver a personalized training experience. 

Portfolio Manager: 
www.leikr.comCristiano Cairo (CMO), Lars Møller (CTO)

Libratone

Wireless speakers

Technology: 

Libratone designs and develops wireless loudspeakers that stream music and audio wirelessly in excellent quality from which ever unit contains the user's music library (e.g. Apple iPod/iPhone/iPad, Mac or PC). Libratone speakers bring back the notion of high quality audio to the world of portable devices and adapt the audio experience to the way consumers live today.

Value Proposition: 

Libratone provides a user-friendly wireless solution with great sound quality and strong appeal to design oriented buyers. Mixing different areas of expertise, from audio technology to design, Libratone aims to bring out the best of Scandinavian design and acoustic performance.

Portfolio Manager: 
www.libratone.comTommy Andersen (CEO), Lars Andersen (CoB)

Light Extraction

LED solutions

Technology: 

Light Extraction has invented a method to grow nanostructures on LED- substrates. This is done by use of equipment, LED-manufacturers already use in their production lines. The time- and cost-efficient solution is aimed at reducing internal reflection in LEDs, which today causes 75% of the energy in high-performing LEDs to be lost as heat instead of producing light.

Value Proposition: 

The light efficiency of LEDs increases dramatically when the internal reflection is reduced. Consequently, it is possible to either increase the amount of light emitted from LEDs or to decrease the energy input. Furthermore, the lifetime and quality of LEDs is also improved, since heat is the most important factor determining their lifetime and performance.

Portfolio Manager: 

Mofibo

E-book service

Technology: 

Mofibo offers a subscription based book service, making thousands of book titles available for consumers, for a low monthly fee. The Mofibo platform allows book lovers to access novels, fiction, children’s books and many more from their tablet, computer and smartphone. 

Value Proposition: 

Today, being a book reader has many drawbacks. It is expensive and the discovery process in bookstores leaves much to be desired. With Mofibo there is no more waiting lists and unavailable books at the library. Subscribers will have unlimited access to thousands of interesting books and can now read on the way to work, on the beach and in their favorite chair in the living room. Mofibo also features a social element allowing people to share reading lists and discover what other people are reading and recommending.     

Portfolio Manager: 
mofibo.comMorten Strunge

MYTRND

Lookbook aggreagtor

Technology: 

MYTRND has developed a platform that aggregates and curates lookbooks from the fashion industry. MYTRND allows fashion brands and buyers to engage with each other in a much more meaningful way than any existing alternative.

Value Proposition: 

The fashion industry typically meets 2-4 times a year at trade fairs and fashion shows. Previous to these gatherings fashion brands have produced lookbooks to present their styles. Subsequently, buyers spend a significant amount of time getting an overview of products and trends and figuring out what to buy. The MYTRND platform allows fashion brands to be discovered and connected to thousands of professional fashion buyers including boutiques, department stores and web shops from all over the world. 

Portfolio Manager: 

Napatech

Network adapters

Technology: 

Napatech develops and markets advanced programmable network adapters for network traffic analysis and application off-loading. Use of FPGA technology and easy-to-use software driver interfaces allows for fast integration and an excellent migration path to Ethernet connections speeds.

Value Proposition: 

With increases in network traffic and Ethernet connectivity speeds, the capabilities of standard network monitoring systems have difficulty providing accurate and reliable measurement and analysis solutions. Napatech offers the technology that delivers hardware acceleration and server off-load increasing the OEMs' ability to maintain their competitive advantage. Napatech has customers worldwide and offices in Denmark and USA.

Additional Information: 

Co-Investors: Northzone Ventures, Ferd Venture

Portfolio Manager: 
www.napatech.com Henrik Brill Jensen (CEO), Olav Stokke (CoB)

Penneo

Digital signing of documents

Technology: 

Penneo has developed an electronic signature solution that enables companies to procure legally binding documents from stakeholders. The costumer uploads the document that needs signing and invites the other party to sign. If the invitation and content of the document is approved, Penneo places a legally binding signature on the document using an electronic identification system (in Denmark this is Nem-ID) and provides both parties with a signed PDF copy.

Value Proposition: 

Each year billions of documents are sent between companies and their stakeholders to secure legally binding signatures. This method is slow and expensive for both company and stakeholder. The electronic signature solution developed by Penneo speeds up the process and is cost effective, saving companies the process of printing, manually signing and scanning all the documents involved. Penneo is online based which removes the need for expensive delivery services. Furthermore Penneo provides companies with a storage solution that saves every signed document at a single location and ensures their safety. 

Portfolio Manager: 
www.Penneo.comMorten Damgaard (CEO)

Sensorist

wireless sensor system

Technology: 

Sensorist is a range of small wireless sensors collecting measurement data about your environment. The measurement data is transferred to the Cloud and the user can then access it via an App or an Internet browser.

Value Proposition: 

The sensor system allows users to measure the things they care about in and around their private homes or businesses. Real-time and historic measurement data can be visualized and explored in a user-friendly way on-the-go and the user can e.g. receive alerts when something unexpected is happening. Sensorist’s first solution is a wine cellar application, which allows users to track temperature and humidity development, to use automated surveillance service to protect wines and to estimate maturity of wines.

Portfolio Manager: 

Sepior

Secure cloud storing

Technology: 

Sepior has developed a Key management System that can solve the problem of security for people storing data in the cloud. The solution consists of an application programming interface and a key management solution

Value Proposition: 

Today more than 50 % of all companies use cloud computing and applications based on cloud computing. However, cloud computing entails a number of security breaches, which put company data at risk. The system developed by Sepior allows users to continue using their preferred applications e.g. ICloud, Dropbox, Google drive and does not require infrastructural changes. Sepior offers a secure way of storing data in the cloud with minimal interference.

Portfolio Manager: 
www.sepior.comNicolaj Høyer Nielsen

SiOx

Metal coating

Technology: 

SiOx has invented a technology that can combine the properties of glass and metals by applying a thin film layer of glass on metal surfaces. This technology combines the desirable inert properties of glass with the desirable ductile properties of metals resulting in a corrosion resistant material. The technology can successfully be applied to all applications where corrosion protection is necessary. Initially, SiOx will focus on the market for heat exchangers.

Value Proposition: 

The technology allows for the manufacturers to produce metal that has high strength and is easy to handle, while also being corrosion resistant and having a low drag coefficient. This will enable manufacturers to substitute expensive corrosion resistant metals with cheaper corrosive metals.

Today, heat exchangers are made with stainless steel or titanium. SiOx’ technology lets manufacturers replace these materials with aluminium, which is four times cheaper than stainless steel and has a heat conductivity, which is ten times higher. The technology can therefore drastically lower the production  costs for heat exchangers.

Portfolio Manager: 
Søren Svanebjerg

SporterPilot

Sport applications

Technology: 

SporterPilot has developed a sports applications for TV sports broadcasters, online sports content distributors, stadiums and betting agencies, which allows sports fans to customise and enhance the digital sports experience. With SporterPilot, sports fans can choose what they want to see and when and how they want to see it, and be supplied with a series of unique recommendation tools that give them instant appraisal of all live and pre-recorded sports action. The SporterPilot application is based on a process through which sports-specific algorithms are applied to sports metadata and live TV feeds in order to filter, evaluate, and customise to each sports-fan's demands.

Value Proposition: 

The technology developed by SporterPilot allows sports fans to receive an enhanced, fulfilling and personalised sports experience, which supports traditional TV media by delivering a wide range of new interactive tools. SporterPilot lets consumers follow their favourite teams, leagues and players simultaneously, while also being able to interact with live and post game sports videos and supporting statistics. 

Portfolio Manager: 

TRD Surfaces

Surface engineering for excellent wear resistance

Technology: 

TRD Surfaces has developed a new technology for hardening steel surfaces. Through a gaseous process, TRD Surfaces modifies the surface of steels by growing an extremely hard and wear resistant layer consisting of carbides or nitrides. The obtained surface hardness can exceed even that of synthetic diamond-like coatings. 

Value Proposition: 

TRD Surfaces offers products with superior wear resistance and lower costs as a substitution for the high cost products used at the moment. TRD Surfaces improves lifetime of components and reduces downtime thereby lowering operating costs. At the same time TRD Surfaces offers cost reduction through the use of lower cost base materials than existing not surface treated alternatives.

The technology behind TRD Surfaces has the potential to replace the existing alternatives and open up new markets due to the superior properties of the product. 

Portfolio Manager: 
www.trdsurfaces.dkMads Brink Lauersen(CEO), Kristian Vinter Dahl(Tech Consultant)

Trustpilot

Online reputation management

Technology: 

Trustpilot is a web portal where consumers rank companies based on their customer service. Besides ratings done via www.trustpilot.com rankings of companies is gathered through information from governmental sources, consumer organizations, media coverage and all ratings and customer reviews on shopping portals, price comparison sites, blog discussions etc.

Value Proposition: 

The Trustpilot service facilitates the trust building process between vendor and consumer, which creates a more comfortable environment for consumers to shop in. Trustpilot offers vendors a partnership package which they can use to actively work with Trustpilot as part of their website and sales cycle.

Portfolio Manager: 
www.trustpilot.dk Peter Holten Mühlmann (CEO), Tim Weller (NEC)

Vivino

Wine app

Technology: 

Vivino is a mobile app which can recognize wine labels via image recognition among millions of existing wines on the market. It provides an easy and fun way of rating and storing wine experiences – and sharing these with friends.

Value Proposition: 

Most wine consumers have found themselves at a dinner party or in a restaurant drinking a wine that they really like - and would like to buy for future consumption, but rarely has this resulted in an actual purchase. This is partly due to a very fragmented market with a huge number of producers and a very large number of importers, distributors and vendors.

Vivino bridges the gap between tasting a great wine and buying it - when the impulse to buy is strongest.

Portfolio Manager: 
www.vivino.comHeini Zachariassen (CEO), Niels Vejrup Carlsen (CoB)

watAgame

Social network gaming

Technology: 

watAgame produces, publishes and operates the social network game goSupermodel - a fashion themed game that allows its users to style their own model character. Characters can interact with their peers in the virtual fashion community, attend photo-shoots, dance competitions, design their own clothing lines and make new friends. WatAgame uses moderators and a sophisticated safety software system to ensure a safe and wholesome experience for the users.

Value Proposition: 

goSupermodel is aimed at 10-16 year old girls and the key focus is personal expression, creativity and imagination. By earning (playing) or purchasing points the girls can add features, clothes, etc to their online avatar. Additionally watAgame's revenue is based on advertising.5 million unique visitors visit goSupermodel every month from 8 different countries.

Additional Information: 

Co-investors: Vækstfonden, Accel Partners

Portfolio Manager: 
www.gosupermodel.comwww.watagame.comHenrik Riis (CEO), Henrik Dyring (CoB)

Windar Photonics

Wind turbine optimisation

Technology: 

Windar Photonics has developed a sensor, WindEye that measures the wind's direction and speed up to 100 meters ahead of the wind turbine. This gives the turbine time to adjust its position and angles of its wings in due time to be optimised for changing wind conditions.

Value Proposition: 

Windar Photonic's WindEye provides wind turbine owners and manufacturers with a 3-5% increase in power production as well as a 10% less stress on the vital components of the wind turbine.  

Additional Information: 

Co-investors: Several business angels

Portfolio Manager: 

Medtech

Minimize

Denmark is a significant hotspot for medical tehnologies with top level research institutions and several major pharmaceutical companies. It is SEED Capitals intent to seek out companies that can build upon or utilize the unique competencies within the Danish ecosystem.

Acarix

Diagnostics of artery constrictions

Technology: 

Acarix is developing a product, which, by listening to the passage of blood through the arteries surrounding the heart will give an indication of whether a patient has stenosis, which can lead to a heart attack. The product is an advanced microphone attached to the patient's chest that within three minutes is able to assess whether the blood passage through the arteries is so turbulent that there is a need to investigate further.

Value Proposition: 

In the western world heart attacks is the most common cause of death, and for a quarter of incidents this happens entirely without warning. Acarix will save lives by - as part of the general practitioners investigation - discovering which patients need further examinations. In addition, every second of the current used costly cardiac examinations shows that the patient does not require treatment. Acarix will spare patients of being subjected to unnecessary invasive radiological studies and will also help health practitioners target when to use the more extensive examinations.

Additional Information: 

Co-Investors: Coloplast, Seventure, Sunstone Capital

Portfolio Manager: 
www.acarix.com Peter Samuelsen (CEO)

Acesion Pharma

Treatment of atrial fibrillation

Technology: 

Acesion Pharma is developing more efficacious and safer drugs for the treatment of atrial fibrillation (AF). The scientific target is the so-called SK channels, an ion channel which is also present in the heart where it is relevant for the regulation of the cardiac rhythm. Acesion Pharma have shown that inhibition of SK channels both protect against induction of AF and reverts sustained AF with efficacy comparable to the gold standard amiodarone

Value Proposition: 

Atrial fibrillation (AF) is the most common type of cardiac arrhythmia and it mainly affects the elderly population. AF often causes a pronounced decrease in quality of life and furthermore increases the risk of stroke. Existing drug therapies only have a limited effect and produces risks of serious adverse events. Therefore, there is a considerable need for developing better and safer drugs. Inhibition of SK channels constitute a novel and promising drug target for the treatment of AF, and Acesion Pharma aims to develop a first-in-class SK inhibitor for the acute cardioversion of AF.

Additional Information: 

Co-Investors: Novo Seeds

Portfolio Manager: 
www.acesionpharma.comUlrik S. Sørensen (CEO), Morten Grunnet (CSO)

Alkalon

Medicated chewing gum

Technology: 

Alkalon is a specialty pharmaceutical company focused on developing and commercializing medicated chewing gum formulations. The company is working in partnership with large pharmaceutical companies on dosage form development projects and has its own portfolio of nicotine gums approved for smoking cessation and smoking reduction. Alkalon's own products are commercialized through license and supply agreements with OTC companies in Europe and elsewhere who market and distribute Alkalon’s products under their own brands.

Value Proposition: 

Alkalon is interested in license and supply agreements with OTC and pharmaceutical companies and offers contract development of finished product formulations. The company utilize a reliable supply chain with high production capacity and competitive prices and is currently supplying several pharmaceutical companies with high quality products, packed and ready for sale.

Portfolio Manager: 
www.alkalon.com Bo Tandrup (CEO), Pal Helmich (COB)

Aros Pharma

Irritable Bowel Syndrome pain treatment

Technology: 

Aros Pharma is developing a new effective therapy reducing the pain associated with Irritable Bowel Syndrome (IBS). The company has acquired all rights to a new chemical entity that can negatively modulate the activity of acid sensors in the gastrointestinal tract. These acid sensors are believed to play a central role in pain associated with IBS.

Value Proposition: 

Although not life threatening, IBS can seriously impair overall quality of life, and as a result it is one of the most common reasons for visits to primary care physicians and gastroenterologists.

Additional Information: 

Co-investors: Novo Seeds

Portfolio Manager: 

Asante

Disposable drug delivery system

Technology: 

Asante Solutions Inc. (former M2 Medical) has developed a small, disposable insulin pump.

Value Proposition: 

The pump is targeted towards T1 diabetics. It is easy to use, affordable and reliable and it has very strong appeal to patients.Asante received 510K regulatory approvals in USA and expect a commercial launch in 2013.

Additional Information: 

Co-investors: Sunstone Capital, Novo Ventures, Denovo Ventures, LFI Life Science Investments and Thomas, McNerney & Partners

Portfolio Manager: 
www.asantesolutions.comDavid Thrower (CEO), Pete McNerney (Chairman)

Carnad

Clean Label Stock

Technology: 

Based on a cost efficient, environmentally friendly technology using soup bones as a basis, Carnad produces high quality stock for the global food industry.

Value Proposition: 

Carnad’s products consist of pure meat containing no artificial ingredients – also known in the industry as clean label products. Clean label is increasingly in demand by consumers and therefore also by the industry.

Furthermore - due the high level of meat - the stock is rich in umami flavour and transforms the currently obtainable flat and salty taste profile into a full and rich taste profile;.

Portfolio Manager: 

COMBAT Stroke

Acute stroke management

Technology: 

COMBAT Stroke has developed a software tool for supporting acute stroke management, helping clinicians, experts as well as non-experts evaluating the effect of a stroke. COMBAT stroke provides the user with invaluable diagnostic assistance in emergency situations. The COMBAT Stroke software will be able to draw up the infarct-area within 30 seconds, locate perfusion area from images within 30 seconds and evaluate mismatch and generate a volume number of salvageable tissue. The invention may be used as a decision support system in a clinical setting, or as a tool for evaluation of treatments. 

Value Proposition: 

Stroke is one of the leading causes of death worldwide and the single-most significant factor for successful outcome is the time from onset to treatment. Today, assessment of images requires an experienced expert to evaluate the infarct area. The evaluation takes several minutes and this time might influence the development of the infarct and can cause additional damage to the brain. COMBAT Stroke will save lives and reduce severity of disability, as a result of Stroke. It will facilitate more time for patient care and reduce the socio-economic burden for society.

Portfolio Manager: 
Kim Mouridsen

Contera Pharma

Drugs for removing movement disorders

Technology: 

Contera Pharma develops new drugs by combining safe and well-documented substances in a unique way.

Value Proposition: 

Parkinson's disease and Schizophrenia are today treated with drugs that - to some extent - are able to eliminate the disease symptoms, but in turn result in highly annoying involuntary movements. These adverse effects, for which there is no good treatment, significantly reduce quality of life and can be so massive that the diseases cannot be optimally treated. Contera Pharma drugs will ameliorate movement disorders including those associated with treatment of Parkinson’s disease and Schizophrenia.

Portfolio Manager: 
www.conterapharma.comSissel Vorstrup (COB), John Bondo Hansen (CEO), Mikael Thomsen (CSO)

Conrig Pharma

Treatment of atopical dermatitis

Technology: 

Conrig Pharma will reposition drug molecules with attractive safety and efficacy profiles through simple modifications and reformulations to provide fast development of new treatments of illnesses. Initial focus will be on a development of a new drug for oral treatment of atopic dermatitis (a type of eczema).

Value Proposition: 

Current oral treatments of atopic dermatitis are inefficient and there is little innovation towards new treatments. Conrig Pharma aim to develop a new safe and effective agent for this growing market.

Portfolio Manager: 
www.conrigpharma.com Sissel Vorstrup (COB), John Bondo Hansen (CEO), Mikael Thomsen (CSO)

Dep-Xplora

Prodrugs for pain relief

Technology: 

Dep-Xplora has invented novel prodrugs of clinically used NSAIDs (non-steroidal anti-inflammatory drugs) to be used in the development of depots for joint injection . Oral  NSAIDs are widely used as rescue medicine to relieve moderate to severe postoperative pain after minor joint surgery  and to alleviate inflammatory pain associated with various arthritis conditions. After injection into a joint such as the knee, the Dep-Xplora prodrug forms a depot at the site of action from which the active NSAID is released over a time period, e.g. 4-10 days.

Value Proposition: 

Dep-Xplora’s mission is to provide superior pain relief of joint associated pain based on peripheral sustained NSAID action after joint injection. By using this delivery concept, the pharmacologically effective concentration of the NSAID can be reached using less than 0.04% of the dose needed to obtain the target site after oral administration. The prodrug approach taken enables establishment of high drug concentration to manage pain and inflammation at the site of action and at the same time minimizes the risk of systemic adverse events.

Portfolio Manager: 

Diet4Life

Protein Hydrolysates

Technology: 

Diet4life is working towards verifying whether protein hydrolysates have superior weight management abilities. Diet4life’s mission is to evaluate the long-term effects of regular protein intake in conjunction with certain food products and the suitability for being a dietary supplement.

Value Proposition: 

Lifestyle related diseases such as diabetes and obesity pose an increasing challenge to humanity and the health care systems in most parts of the developed world. A common problem with protein hydrolysates and their incorporation into food products is their pronounced bitter taste. The value proposition of Diet4life relates to the use of non-bitter protein hydrolysates in diets to reduce fat accumulation and, possibly, induce weight loss in the human body. 

Portfolio Manager: 

EmbryoTrans Biotech

Improving bovine artificial insemination

Technology: 

EmbryoTrans Biotech aims at providing both cattle breeders and breeding laboratories with better products and higher productivity. EmbryoTrans Biotech has developed a new way to increase bovine cattle reproduction by raising embryo survival rate and ensuring high pregnancy rates. 

Value Proposition: 

Because of the rising demands on milk and meat, an increase in livestock production has become paramount to ensure and increase food supply. Natural mating and artificial insemination are slow and inefficient by only allowing a range of 10-15 offspring in the lifespan of a cow. In-Vitro-Fertilization (IVF) on the other hand allows for up to 300 offspring in a lifespan; a significant increase in production. EmbryoTrans Biotech produces serum free media to use in connection with In-Vitro-Fertilization of cattle; increasing embryo survival rate by 100% and thereby decreasing the costs involved with IVF and making the technology widely available. IVF is one of the most efficient ways to improve livestock production and EmbryoTrans Biotech has the technology and knowhow to ensure its success. 

Portfolio Manager: 
Jan Bertholdt Hansen (CEO)

EpiTherapeutics

Cancer treatment in the field of epigenetics

Technology: 

EpiTherapeutics is developing novel innovative cancer drugs based on the world leading research in epigenetics conducted by Professor Kristian Helin and his group at Biotech Research & Innovation Centre (BRIC) at University of Copenhagen.Epitherapeutics is currently building a strong IPR platform based on proprietary knowledge within histone demethylases and methyltransferases and via in-house drug discovery efforts to identify small molecule inhibitors of key enzymes within the family targeting unmet medical needs.

Value Proposition: 

The development of so-called epigenetic drugs is regarded as an important point of intervention for the treatment of cancer. The scientific discoveries of EpiTherapeutics have potential applications in a wide range of clinical indications, but the company's initial focus will be on prostate cancer.

Additional Information: 

Co-investors: Novo, The Lundbeck Foundation, OSI Pharmaceuticals, Merck Serono Ventures 

Portfolio Manager: 
www.epitherapeutics.dk Martin Bonde (CEO), Peter Høngaard Andersen (CoB)

Galecto Biotech

Treatment of IPF

Technology: 

Galecto Biotech develops a novel drug for the deadly lung disease called Idiopathic Pulmonary Fibrosis (IPF). IPF is an orphan decease affecting about 30.000 Americans every year.

Value Proposition: 

IPF is characterised by a condition in which over a period of time the lung tissue becomes thickened, stiff, and scarred.  As a result, the brain and other organs don't get the oxygen they need with fatal consequences. There is currently no cure for this decease.

Additional Information: 

Co-Investors: Novo Seeds, MerckSerono Ventures and Sunstone Capital

Portfolio Manager: 
www.galecto.comHans Schambye (CEO)

Glycom

Novel biomolecules for the pharmaceutical and food industries

Technology: 

Glycom's principal activity is to develop and sell new biomolecules to the food ingredient industry. The company has unique know-how and abilities within carbohydrate chemistry, which it utilizes for the development of industrial scale production of Human Milk Oligosaccharides (HMOs). HMOs are high value ingredients in infant formula and potentially other functional food products. Glycom is presently developing, in its own laboratories, synthetic processes for the preparation of selected HMOs, which are suitable for multi-ton scale production.

Value Proposition: 

HMOs are not found in cow milk and therefore currently not available in infant formulas. HMOs are documented to have prebiotic effects (nutrition for healthy intestinal bacteria) and to have important antibacterial/antiviral effects as well as stimulating early brain development on infants. Glycoms ability to synthetically produce HMO at a reasonable price will allow producers of - in particular - infant formula to offer their products with HMO.Glycom has a long-term cooperation agreement and partnership with Nestlé Nutrition and has initiated a second wave of HMO development and pre-industrialization in the beginning of 2010.

Additional Information: 

Co-investors: Private

Portfolio Manager: 
www.glycom.dk John Theroux (CEO), Kim Bøtkjær (COB), Gyula Dekany (CSO)

InnoCC

Monitors critically ill patients

Technology: 

InnoCC is developing a device used for monitoring critically ill patients being ventilated in a respirator. The device monitors cardiac output, which is the amount of blood that the heart pumps around the body. This is done through a non-invasive method. Cardiac output is an important vital sign and monitorization provides health care professionals with information about the patient’s condition and is therefore essential to the survival and recovery speed of the patient.

Value Proposition: 

At the moment, measurement of cardiac output is done through an invasive procedure. A non-invasive procedure, such as the one developed by InnoCC therefore has huge benefits. InnoCC offers improved survival rate of patients and reduced costs of treating patients by reducing their hospital stay, reducing the cost of care and reducing the probability of a patient returning to the hospital. 

Portfolio Manager: 
Martin Stenfeldt(CEO)

Intomics

Biological data analysis

Technology: 

Intomics is a contract research company with leading expertise in biological data analysis and mining, bioinformatics and systems biology. Their services include data mining and data combination, network analysis, target prioritization, text mining, and core bioinformatics services. The analyses are unique and customized to the individual project.

Value Proposition: 

Based on their proprietary tools, unique knowledge, and ability to customize solutions to meet the need of each client, Intomics can improve biological and clinical research in areas such as biomarker discovery and optimization, extraction of biological knowledge from data, drug discovery and translational research. The advanced data analyses will enable the pharmaceutical industry to get the most out of trials and research in new drug candidate, so as to discover drug and diagnostic targets cheaper and faster.In a ten-year perspective, integrative approaches like Intomics will form the basis for advanced, quantitative and qualitative types of systems biology, where simulation and modelling will be a key for the understanding of complex diseases and their underlying causes at the molecular level.In 2010 Intomics entered into collaboration with Danish pharmaceutical company Leo Pharma. 

Portfolio Manager: 
www.intomics.comThomas Skøt Jensen (CEO)

Levoss

Nano-material for treating musculoskeletal conditions

Technology: 

LevOss is developing a biodegradable material (polymer) embedded with a Nano mesh, that will be able to fit into a bone fracture or void site. The material provides mechanical stability equivalent to the native tissue and provides an environment optimized for stem cell guidance and thereby new tissue generation.

Value Proposition: 

Musculoskeletal conditions are the most common causes of severe long-term pain and physical disability, affecting hundreds of millions of people across the world. The condition is increasingly treated by transplanting synthetic solutions that however does not adhere to the bone sufficiently well.
LevOss will be able to deliver a transplant material that integrates more effectively with the bone while also providing conditions for new tissue generation.

Portfolio Manager: 
www.levoss.comMai-Britt Zocca (Interim CEO)

Medichanical Engineering

Device for hip-replacement surgery

Technology: 

Medichanical Engineering is developing the X-pander. A mechanical measuring device, that will help hip-replacement surgeons objectify the needed level of component size and whether the damaged bone has been sufficiently reamed.

Value Proposition: 

The increasingly popular press-fitting technique for hip-replacements demands very precise manual surgeon skills. Both in regards to the size of the needed prosthetic component as well as whether the component will fit into the pelvic bone. If these estimates are not done correctly additional surgery is a risk resulting in added cost as well as discomfort for the patient. The X-Pander will help decrease these cases with at least 50%.

Portfolio Manager: 
www.medichanical.comEske Winther Petersen (CEO)

Minervax

Vaccine against GBS infections

Technology: 

Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains.

Value Proposition: 

GBS is the leading cause of life-threatening bacterial infections in newborn babies and GBS has recently been reported to cause an increasing number of serious infections in the adult population. The National Institute of Health of the US has identified prevention of GBS in newborns as a major vaccine objective, but so far no approved or universally useful vaccine exists. A general vaccine effective against relevant strains of GBS is poised to have great impact and could potentially be administered to pregnant women or women considering pregnancy as part of a general vaccine program.

Portfolio Manager: 

Motility Count

Disposable sperm test

Technology: 

Motility Count is developing a single-use sperm quality checker, which measures both the quality and quantity of the semen within 30 minutes.

Value Proposition: 

16% of all couples in the developed world that whishes to get pregnant have to seek assistance at In Vitro Fertilization. Half is linked to sperm quality. The Motility Count product will increase the privacy for these couples by eliminating the need to visit IVF specialist/hospital for (initial) testing of sperm.

Motility Count was awarded the Invention of The Year at the 2011 Scandinavian Industry Expo (HI11)

Additional Information: 

Coinvestors: Several business angels

Portfolio Manager: 

Nanovi

Cancer treatment

Technology: 

Nanovi has developed a new, patented product - NanoGel. NanoGel improves precision in radiotherapy treatment for cancer patients and can be used in the treatment of several types of cancer, including lung cancer. NanoGel is a goal-coated liquid marker, which is to be injected directly into the tumour for greater precision.

Value Proposition: 

Cancer is a leading cause of death worldwide and poses severe problems for humanity. More than 50% of all cancer patients receive radiotherapy at least once during their illness trajectories. NanoGel greatly improves the precision of radiation therapy without compulsory changes in current routines and equipment. The more precise treatment of cancer cells prevents unnecessary damage to healthy tissue.

Portfolio Manager: 
www.nanovi.dk/Morten Albrechtsen

Neurescue

Treatment of cardiac arrest

Technology: 

Neurescue is developing a new class of medical devices for the treatment of cardiac arrest. Neurescue aims to be the foundation of a new platform of treatment methods for paramedics, nurses and doctors alike. The new treatment will greatly improve the current rates of resuscitation and thereby the outcome of cardiac arrest. 

Value Proposition: 

Cardiac arrest costs lives and at the moment only 1 out of 10 persons survive the condition. Isolated cardiac arrests outside of hospitals amount to 360.000 cases annually in USA and between 350.000 and 700.000 cases annually in EU. The numbers of in-hospital cardiac arrests are at least as high. As the numbers suggest there is a need for devices that help save people with cardiac arrest and Neurescue seeks to do just that. 

Portfolio Manager: 

NociTech

pain test platform

Technology: 

NociTech has developed a novel advanced pain test platform that enables a mechanism-based quantification of pain sensitivity in patients and profiling of new analgesic compounds under development. The mechanistic approach can differentiate whether the pain is associated with mechanisms in the peripheral or central nervous system affections.

Value Proposition: 

One out of five adults suffers from chronic pain and current preventions and therapies are insufficient. One important factor for not being more successful in treating chronic pain is lack of mechanism-based, objective, bed-side, clinical diagnostic tests to quantify which pain mechanisms are affected and hence should be targeted.  To understand, prevent, diagnose and treat pain, there is an unmet need for quantitative pain testing devices to be utilised by researchers, private clinics, hospitals, pharmaceutical companies and clinical trial units.

NociTech’s technology can distinguish between different patients and quantify how much the pain system is hypersensitive and if it is primarily peripheral or central changes. 

Portfolio Manager: 
Morten Albrechtsen

Nordic NeuroSTIM

Reflex-based rehabilitation

Technology: 

Nordic NeuroSTIM has developed a product called ReFlexFET, which is a medical device for delivering reflex-based rehabilitation to stroke patients. Reflex based rehabilitation consists of detecting the gait cycle of the patient and delivering precisely timed electrical pulses to the sole of the foot. These brief electrical pulses will evoke the withdrawal reflex that will assist the patient in taking a step. Rehabilitation last from 1 to 4 months depending on the severity of the stroke. During rehabilitation the patient will engage in a multitude of sessions; aiming at restoring both cognitive as well as motor skills such as gait.

Value Proposition: 

The reflex-based rehabilitation has the potential of promoting rehabilitation for especially the heavily impaired patients, bringing them from being bound to a wheel chair to being independent walkers. 

Portfolio Manager: 
Kristian Hennings

Observe Medical

Digital Urine Meter

Technology: 

Observe Medical has developed a revolutionary digital urine meter - Sippi. Sippi is an easy-to-use application that monitors urine production via a bag application connected to a piece of software. Sippi is fully automatic during the length of the treatment.

Value Proposition: 

Urin production can be used as a diagnostic tool in the care of patients. However it is normally done manually by nursing staff that collect and journalize the output. Sippi's automatic abilities and data analysing software will allow staff to focus on evaluating data output and patient care, as well as reducing human errors.

Additional Information: 

Co-investors: Sahlgrenska Science Park, M2 Capital Management, Porter & Partners, Lavin Capital  

Oracain

Pain relieve for oral mucositis

Technology: 

Oracain is developing a novel pharmaceutical product for pain associated with oral mucositis and other complex conditions.

Value Proposition: 

Oral mucositis is an adverse effect of cancer chemo- or radiotherapy, where the mucosal lining of the mouth becomes thin, may slough off and then become red, inflamed and ulcerated. The condition is very painful and will often result in patients having trouble speaking, eating, or even opening the mouth. Oral mucositis is the most common distressing and disabling acute complication of cancer chemotherapy and radiotherapy as reported by patients, and is a significant dose-limiting toxicity of cancer therapy. Pain and secondary infections associated with untreated oral mucositis result in substantial increases in hospitalization costs. Development of a new pain relief product for these patients will have a significant impact on quality of life and on the cost of care for cancer patients.

Portfolio Manager: 

Reapplix

Improvements in wound healing

Technology: 

Reapplix offers a novel mechanism to enhance the inherent wound healing capability of the body - the LeucoPatch™. The LeucoPatch™ is made entirely from the patient's own blood without any additives and is therefore fully autologous and biocompatible.

Value Proposition: 

Reapplix' objective is to enable patients to benefit from the wound-healing properties of their own growth promoting factors and thereby provide a treatment option to avoid traumatic amputation surgery. Leucopatch™ increases the healing rate of chronically hard to heal and debilitating wounds thus resulting in increased quality of life for the patient and considerably lower costs for the society. Initially efforts focus on non-healing diabetic foot ulcers.Clinical trials have shown impressive results.

Additional Information: 

Co-investors: Accelerace Invest

Portfolio Manager: 
www.reapplix.comNiels Erik Holm (CEO),
Peter Hentschel (CoB)

Sense

Blood Pressure Sensor

Technology: 

Sense is developing novel methods for cardiovascular sensing and in particular blood pressure and vascular compliance. The technology is a small patch with a sensor that is placed directly on the patient's wrist artery. The patented sensing scheme is based on a concept that does not interfere with the physical or psychological state of the patient, which is in contrast to existing blood pressure measuring methods. It is thus very suitable for continuous ambulatory measurements.

Value Proposition: 

The Sense technology creates new possibilities for easy, comfortable, precise and continuous measurements of blood pressure. Unlike traditional inflatable cuff alternatives the technology enables patients to be monitored in natural situations with negligible discomfort.

Additional Information: 

Co-Investors: Vækstfonden

Portfolio Manager: 
www.sense-as.dk Henrik Wendler (CEO), Lars Lading (CSO), Kurt Erling Brik (CoB)

Victorious Medical Systems

Device for cancer diagnostics

Technology: 

Victorious Medical Systems is developing a device used in cancer diagnostics.

Value Proposition: 

The device will help increase productivity and reduce hands-on procedures in a user-friendly way.

Portfolio Manager: 

Exits

SEED Capital has exited a number of interesting companies to global corporations, business angels and management buyouts.

Minimize

Fullrate

Fullrate was bought by TDC March 2009

Evolva

Evolva was exited through an IPO and the last shares were sold in 2013.

Kaleido Technology

Kaleido shares was acquired by AAC Acoustic in 2011

Wecapack

Wecapack exited through management buy-out in 2010

Swantec

Swantech exited through management buy-out in 2008

TagAway Devices

TagAway Devices exited through management buy-out in 2013

Virogates

Virogates exited through management buy-out in 2007

Image Metrology

Image Metrology exited through management buy-out in 2007

Orthometer

Orthometer exited through UK investor buy-out in 2004